| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition
|
Coco, Simona
|
|
2014
|
10 |
3 |
p. 393-404
|
article
|
| 2 |
Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib
|
Teo, Yi Ling
|
|
2014
|
10 |
3 |
p. 429-437
|
article
|
| 3 |
Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?
|
Allard, M. A.
|
|
2014
|
10 |
3 |
p. 415-421
|
article
|
| 4 |
Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma
|
Li, Jianhong
|
|
2014
|
10 |
3 |
p. 355-363
|
article
|
| 5 |
Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T
|
Tsimafeyeu, Ilya
|
|
2014
|
10 |
3 |
p. 423-427
|
article
|
| 6 |
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer
|
Mardjuadi, Feby Ingriani
|
|
2014
|
10 |
3 |
p. 375-383
|
article
|
| 7 |
Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry
|
Kubackova, Katerina
|
|
2014
|
10 |
3 |
p. 385-392
|
article
|
| 8 |
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC)
|
Kwok, C. W.
|
|
2014
|
10 |
3 |
p. 365-373
|
article
|
| 9 |
Regorafenib: start low and go slow
|
Tabchi, S.
|
|
2014
|
10 |
3 |
p. 445-447
|
article
|
| 10 |
Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle
|
Thijs, Anna M. J.
|
|
2014
|
10 |
3 |
p. 439-443
|
article
|
| 11 |
Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack
|
Cinci, Marc
|
|
2014
|
10 |
3 |
p. 405-413
|
article
|
| 12 |
Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals
|
Kadioglu, Onat
|
|
2014
|
10 |
3 |
p. 337-353
|
article
|
| 13 |
The route to personalized medicine in bladder cancer: where do we stand?
|
Massari, Francesco
|
|
2015
|
10 |
3 |
p. 325-336
|
article
|
| 14 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies
|
Covell, Lorinda L.
|
|
2015
|
10 |
3 |
p. 311-324
|
article
|
Journal description